Charlie Taylor

Prior to MMS, Dr. Taylor worked at Pfizer, formerly with Parke-Davis, for more than 25 years. There, he supervised and managed a laboratory of scientists involved in early stages of drug discovery in fields that included neurological diseases, epilepsy, neuropathic pain, stroke, anxiety, sleep disorders, bipolar disorder and schizophrenia.

At Pfizer, Dr. Taylor coordinated research efforts and peer-reviewed publications from Pfizer research sites and outside labs directed toward pharmacology and mechanisms of action of gabapentin and pregabalin, summarized pharmacology for FDA approval and for estimation of clinical dosages, and responded to pharmacology queries from US and EU regulatory agencies. Additionally, he compiled and interpreted safety pharmacology studies with drug candidates, designed and managed studies of drug mechanism of action (in vitro and in vivo methods), collaborated with ADME / pharmacokinetic scientists (e.g. pharmacological activity of drug metabolites; determined safety ratios; determined cardiac safety, etc.), and led collaborative project teams (pharmacologists, chemists, ADME, toxicologists) to discover new drug candidates.

An invited speaker at workshop and conferences, Dr. Charlie Taylor holds a Ph.D. in Neurobiology from the University of California, Berkeley and a Bachelor of Arts in Zoology from the University of Texas.

Suggested For You

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium